You can now get paid for - but probably will not profit from - Lucentis injections

Article Overview

This article covers Medicare and carrier coverage considerations for Lucentis injections used in wet age-related macular degeneration, including the relationship to Avastin as an off-label alternative, reimbursement concerns, and the importance of local coverage determinations. It is intended for ophthalmology practices, coders, and billing staff who need to understand how payer policy, patient cost-sharing, and diagnosis documentation can affect claims processing. The piece also touches on federal study uncertainty, informed consent, and advance beneficiary notice considerations when coverage is unclear.